RemeGen Co., Ltd.
RemeGen Co., Ltd. has 1 licensing announcement in this dataset, dated 2026-01-12.
- Country / operating region
- China
- Ticker
- 09995.HK; 688331.SH
- Headquarters
- Yantai, Shandong, China
- Founded
- 2008
- Business
- Biopharmaceutical research, development, manufacturing and commercialization
- Website
- www.remegen.com
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| RC148 | PD-1; VEGF | bispecific | 查無 | 2026-01-12 |
| Asset | Registered / announced phase | Trial | Status | Sponsor | Record date |
|---|---|---|---|---|---|
| RC48-ADC | PHASE3 | NCT05302284 | RECRUITING | RemeGen Co., Ltd. | 2023-12-18 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2026-01-12 | AbbVie | RC148 | USD 650m | 查無 | ≤ USD 4950m | 查無 | — |
| Counterparty | Territory | Royalties |
|---|---|---|
| AbbVie | Worldwide excluding Greater China | Tiered double-digit royalties on net sales outside Greater China. |
Asia ADC assets and licensing deals
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無
Drugnews analysis
查無